Open an account

Biomerieux SA

BMXMF · NYSE

$100.57+$5.57 (+5.86%)TodayMarket closed ·
No price history for this range.

About BMXMF

bioMérieux SA engages in the provision of in vitro diagnostic solutions, which determine the source of disease and contamination. The company employs 15,226 full-time employees The company went IPO on 2004-06-07. The firm designs, develops, manufactures and sells systems used in clinical applications, such as for the diagnosis of tuberculosis, respiratory infections, among others and industrial applications, such as for the analysis of industrial or environmental samples. The firm also provides its customers with related services for the installation and maintenance of instruments, and training for product users. BioMerieux SA operates through its numerous subsidiaries in various countires, including bioMerieux Deutschland GmbH, bioMerieux Austria GmbH, Advencis, bioMerieux Benelux SA/NV, as well as BioFire Diagnostics Inc., chromID CARBA SMART and new bi-plate Petri dish.

Employees
15,226
Headquarters
Craponne, Auvergne-Rhone-Alpes
Listed
Jun 7, 2004
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
biomerieux.com

BMXMF key statistics

Market cap
10.25B
Price-earnings ratio
0.00
Dividend yield
1.12%
Average volume
119
Volume
100
Open price
$100.57
High today
$100.57
Low today
$100.57
52 Week high
$152.00
52 Week low
$77.00

Biomerieux SA (BMXMF) at a glance

As of Oct 15, 2026, Biomerieux SA (BMXMF) shares are priced at $100.57, giving the company a market cap of 10.25B, a price-to-earnings ratio of 0.00 and a dividend yield of 1.12%.

Volume so far is 100 shares, in line with the average of 119 shares a day.

Over the past year Biomerieux SA has ranged from $77.00 to $152.00, and now sits 31% of the way up that range.

Biomerieux SA met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported $1.99 per share against an estimate of $2.02.

BMXMF earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 9.8% on average.

  1. Q4 FY21: reported $2.75 per share against an estimate of $2.37
  2. Q2 FY22: reported $1.93 per share against an estimate of $2.24
  3. Q4 FY22: reported $1.89 per share against an estimate of $2.18
  4. Q2 FY24: reported $1.82 per share against an estimate of $1.77
  5. Q4 FY24: reported $2.04 per share against an estimate of $2.17
  6. Q2 FY25: reported $1.35 per share against an estimate of $2.24
  7. Q4 FY25: reported $2.30 per share against an estimate of $2.08
  8. Q2 FY26: reported $1.99 per share against an estimate of $2.02

BMXMF news

  • Press releasePRNewswire

    bioMérieux Unveils its BIOFIRE® SPOTFIRE® Molecular Testing Solution for the Pharmaceutical Industry, Redefining Rapid Mycoplasma Testing

  • Press releasePRNewswire

    bioMérieux launches SMARTBIOME™ to help food manufacturers gain deeper insights into spoilage and protect product quality

  • Press releasePRNewswire

    OhioHealth Partners with bioMérieux as Newest Global Antimicrobial Stewardship Center of Excellence

Similar companies

Companies in the same industry as Biomerieux SA

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.